Grace Lai‐Hung Wong
YOU?
Author Swipe
View article: Chronic Hepatitis B Infection: Patient Guidance
Chronic Hepatitis B Infection: Patient Guidance Open
This patient guidance document is intended for all people at risk of or living with chronic hepatitis B (CHB) infection. Globally, CHB is one of the leading causes of cirrhosis and hepatocellular carcinoma, the most common form of liver ca…
View article: Body-wide multi-omic counteraction of aging with GLP-1R agonism
Body-wide multi-omic counteraction of aging with GLP-1R agonism Open
Identifying practical ways to counteract aging and associated degenerative disorders is urgently needed. We performed deep molecular profiling and functional assessments in aging male mice to show that glucagon-like peptide-1 receptor agon…
View article: Histological severity and hepatic outcomes in patients with MASLD and discrepant FIB-4 and liver stiffness measurement
Histological severity and hepatic outcomes in patients with MASLD and discrepant FIB-4 and liver stiffness measurement Open
Approximately 30% of patients in tertiary centers exhibit discordant FIB-4 and LSM results, with LSM more likely reflecting true severity. While some patients with discordant results may have advanced fibrosis, the overall incidence of LRE…
View article: Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial
Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial Open
Functional cure is a goal for the treatment of chronic hepatitis B virus (HBV) infection; however, it is infrequently achieved with currently approved treatments. Here we provide a randomized evaluation of the small interfering RNA elebsir…
View article: Validation of a data-driven clustering model for MASLD: Evidence from three large-scale Asian cohorts
Validation of a data-driven clustering model for MASLD: Evidence from three large-scale Asian cohorts Open
View article: Letters on “Efficacy and Safety of Tenofovir Alafenamide ( <scp>TAF</scp> ) and Tenofovir Disoproxil Fumarate ( <scp>TDF</scp> ) Followed by <scp>TAF</scp> in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment.” Authors' Reply
Letters on “Efficacy and Safety of Tenofovir Alafenamide ( <span>TAF</span> ) and Tenofovir Disoproxil Fumarate ( <span>TDF</span> ) Followed by <span>TAF</span> in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment.” Authors' Reply Open
View article: An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma
An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma Open
View article: #2046 Effect of proton pump inhibitors and histamine-2 receptor antagonists on peritoneal dialysis-associated peritonitis: a territory-wide, propensity-weighted cohort in Hong Kong
#2046 Effect of proton pump inhibitors and histamine-2 receptor antagonists on peritoneal dialysis-associated peritonitis: a territory-wide, propensity-weighted cohort in Hong Kong Open
Background and Aims Proton pump inhibitors (PPI) and histamine-2 receptor antagonists (H2A) are commonly prescribed to patients undergoing peritoneal dialysis (PD), who are prone to gastrointestinal complications, especially with concurren…
View article: Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer
Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer Open
Background Current and past hepatitis B virus (HBV) infection remains the leading cause of liver cancer in endemic areas. Aim To examine the risk of HBV reactivation (HBVr) in patients receiving immune checkpoint inhibitors (ICI) for liver…
View article: Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis
Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis Open
View article: ACCELERATED PROGRESSION TO CIRRHOSIS AND HEPATIC DECOMPENSATION IN METALD AND ALD COMPARED TO MASLD: A GLOBAL STUDY
ACCELERATED PROGRESSION TO CIRRHOSIS AND HEPATIC DECOMPENSATION IN METALD AND ALD COMPARED TO MASLD: A GLOBAL STUDY Open
Introduction and Objectives: The natural history of MetALD remains poorly characterized. In a large global cohort, we compared the natural history of the main steatotic liver disease (SLD) subtypes in terms of liver fibrosis progression an…
View article: Persistent risk of hepatocellular carcinoma despite improvement of liver stiffness in patients with chronic HBV with advanced fibrosis
Persistent risk of hepatocellular carcinoma despite improvement of liver stiffness in patients with chronic HBV with advanced fibrosis Open
View article: 3-011 The impact of hope on cardiovascular disease: a systematic review
3-011 The impact of hope on cardiovascular disease: a systematic review Open
View article: 5-023 Home-management of worsening heart failure with intravenous diuretics is associated with high rates of admission and mortality
5-023 Home-management of worsening heart failure with intravenous diuretics is associated with high rates of admission and mortality Open
View article: Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment
Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment Open
Background Tenofovir alafenamide (TAF) has shown non‐inferior efficacy to tenofovir disoproxil fumarate (TDF), with superior bone and renal safety. Aim To characterise 5‐year TAF efficacy and safety in patients of East Asian ethnicity from…
View article: Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics
Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics Open
Non-alcoholic fatty liver disease (NAFLD), also referred to as metabolic-associated fatty liver disease, is among the most prevalent chronic liver conditions. In some cases, NAFLD may lead to liver inflammation and non-alcoholic steatohepa…
View article: Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era
Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era Open
The classical bimodal recurrence pattern of hepatocellular carcinoma following curative treatment was established prior to the widespread use of effective antiviral therapy. It is unclear whether this recurrence pattern is still valid in t…
View article: Extracellular vesicle-derived miR-425-5p (miR-425) activates astrocytes in the brain to promote breast cancer brain metastasis via the novel miR-425-ZNF24-CCL8 signaling axis
Extracellular vesicle-derived miR-425-5p (miR-425) activates astrocytes in the brain to promote breast cancer brain metastasis via the novel miR-425-ZNF24-CCL8 signaling axis Open
Mechanisms underlying breast cancer brain metastasis (BCBM) are still not well understood. Here, we identified that BCBM patient serum contained extracellular vesicles (EVs) with high levels of microRNAs (miRNAs)-107 and -425. Levels of mi…
View article: “A systematic review of mesh support of the breast in aesthetic breast surgery”
“A systematic review of mesh support of the breast in aesthetic breast surgery” Open
View article: TidyMass2: Advancing LC-MS Untargeted Metabolomics Through Metabolite Origin Inference and Metabolic Feature-based Functional Module Analysis
TidyMass2: Advancing LC-MS Untargeted Metabolomics Through Metabolite Origin Inference and Metabolic Feature-based Functional Module Analysis Open
Untargeted metabolomics provides a direct window into biochemical activities but faces critical challenges in determining metabolite origins and interpreting unannotated metabolic features. Here, we present TidyMass2, an enhanced computati…
View article: The MEFIER Score—A Risk Score to Stratify Infective Endocarditis in Patients With <i>Enterococcus faecalis</i> Bacteremia Based on an 11-Year Territory-Wide Cohort
The MEFIER Score—A Risk Score to Stratify Infective Endocarditis in Patients With <i>Enterococcus faecalis</i> Bacteremia Based on an 11-Year Territory-Wide Cohort Open
Background The 2023 Duke–International Society for Cardiovascular Infectious Diseases (ISCVID) guideline included Enterococcus faecalis as a typical infective endocarditis (IE) organism irrespective of the primary source and setting of inf…
View article: EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection Open
View article: Discriminating between different modified dispersion relations from gamma-ray observations
Discriminating between different modified dispersion relations from gamma-ray observations Open
The fact that the standard dispersion relation for photons in vacuum could be modified because of their interaction with the quantum nature of spacetime has been proposed more than two decades ago. A quantitative model [Jacob \& Piran, JCA…
View article: Cost‐Effectiveness of Universal Screen‐and‐Treat Strategies for Reducing Morbidity and Mortality of Chronic Hepatitis B in a High‐Endemicity City
Cost‐Effectiveness of Universal Screen‐and‐Treat Strategies for Reducing Morbidity and Mortality of Chronic Hepatitis B in a High‐Endemicity City Open
In the setting of high hepatitis B virus (HBV) endemicity, we studied the cost‐effectiveness of universal HBV screen‐and‐treat strategies for averting HBV‐related morbidity and mortality in Hong Kong, where diagnosis and treatment coverage…
View article: Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: A population-based multi-cohort study
Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: A population-based multi-cohort study Open
View article: Pharmacological Treatment of Ascites: Challenges and Controversies
Pharmacological Treatment of Ascites: Challenges and Controversies Open
Ascites is the most common complication from cirrhosis related to portal hypertension and depicts the onset of hepatic decompensation. Ranging from uncomplicated to refractory ascites, the progression carries prognostic value by reflecting…
View article: Doctors’ Work in the Public Hospital Sector in Hong Kong
Doctors’ Work in the Public Hospital Sector in Hong Kong Open
View article: Concomitant Usage of H1‐Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival
Concomitant Usage of H1‐Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival Open
Purpose Recent research (Li et al. 2021) suggests an upregulated expression and activation of H1 receptors on macrophages in the tumor microenvironment, and concomitant H1‐antihistamine use is associated with improved overall survival in p…
View article: P-11 REAL-WORLD DATA WITH PANGENOTYPIC DIRECT-ACTING ANTIVIRALS IN LATINAMERICA: PRELIMINARY RESULTS OF THE SVR10K STUDY
P-11 REAL-WORLD DATA WITH PANGENOTYPIC DIRECT-ACTING ANTIVIRALS IN LATINAMERICA: PRELIMINARY RESULTS OF THE SVR10K STUDY Open
Conflict of interest: Yes, Gilead-sponsored research Introduction and Objectives: A previous real-world data (RWD) analysis demonstrated high effectiveness of sofosbuvir/velpatasvir (SOF/VEL) without ribavirin in > 6,000 HCV patients from …
View article: Updated Guidelines for the Prevention and Management of Chronic Hepatitis B—World Health Organization 2024 Compared With China 2022 <scp>HBV</scp> Guidelines
Updated Guidelines for the Prevention and Management of Chronic Hepatitis B—World Health Organization 2024 Compared With China 2022 <span>HBV</span> Guidelines Open
The year 2024 is the year of new clinical practice and management guidelines for chronic hepatitis B virus (HBV) infection. World Health Organization (WHO) published the updated HBV guidelines in March 2024. In contrast, two key internatio…